General Information of Drug (ID: DMIA3GH)

Drug Name
PMID27977313-Compound-18 Drug Info
Cross-matching ID
TTD Drug ID
DMIA3GH

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fotemustine DMV62ED Solid tumour/cancer 2A00-2F9Z Approved [2]
Spermidine DMVJNFI Plaque psoriasis EA90.0 Phase 3 [2]
Golden phosphorous acetyletic compound 2 DMYJ15A N. A. N. A. Patented [1]
Terpyridineplatinum(II) complexe 3 DM54EFD N. A. N. A. Patented [1]
Terpyridineplatinum(II) complexe 4 DMOV86T N. A. N. A. Patented [1]
Golden phosphorous acetyletic compound 1 DMVAKUI N. A. N. A. Patented [1]
Acyl oxymethyl acrylamide ester derivative 1 DMXTUE1 N. A. N. A. Patented [1]
Triazole gold complexe 1 DMCWES7 N. A. N. A. Patented [1]
4-aryl quinol derivative 2 DM7TW5Z N. A. N. A. Patented [1]
PMID27977313-Compound-46 DMGF04T N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cytoplasmic thioredoxin reductase (TXNRD1) TTR7UJ3 TRXR1_HUMAN Inhibitor [1]

References

1 Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
2 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.